A5060936406- Protein Degradation and Inhibitors
- Acute Myeloid Leukemia Research
- S100 Proteins and Annexins
- Neuroblastoma Research and Treatments
- Chronic Myeloid Leukemia Treatments
- CAR-T cell therapy research
- Acute Lymphoblastic Leukemia research
- Signaling Pathways in Disease
- Cell Adhesion Molecules Research
- Histone Deacetylase Inhibitors Research
Pfizer-University of Granada-Junta de Andalucía Centre for Genomics and Oncological Research
2022-2025
Josep Carreras Leukaemia Research Institute
2022-2024
Instituto de Salud Carlos III
2024
Universitat de Barcelona
2022-2023
Recent research highlighted the contribution of extracellular matrix, and particularly ADAMTS proteases, in immune regulation. Now, our work with melanoma mammary tumor models revealed that blockade induced by lack Adamts1 led to an increased vascular deposition its substrate, basement membrane glycoprotein NIDOGEN-1 (NID1). Significantly, overexpression NID1 syngeneic model also blocked progression, disclosing overlapping phenotype absence Adamts1. These tumors showed important alterations...
Acute myeloid leukemia (AML) is the most common acute in adults. Patients with AML harboring a constitutively active internal tandem duplication mutation (ITDMUT) FMS-like kinase tyrosine (FLT3) receptor generally have poor prognosis. Several kinase/FLT3 inhibitors been developed and tested clinically, but very few (midostaurin gilteritinib) thus far FDA/EMA-approved for patients newly diagnosed or relapse/refractory FLT3-ITDMUT AML. Disappointingly, clinical responses are commonly partial...
B-cell Acute Lymphoblastic Leukemia with MLL gene rearrangements (MLLr B-ALL) is an aggressive subtype of B-ALL (overall survival< 40%), whose patients are usually younger than 1 year and present therapy resistance high relapse rates. Remarkably, the proteoglycan Neuron-glial antigen 2 (NG2), which barely expressed in normal hematopoietic cells, leukemic cells around 90% MLLr patients. However, its role remains elusive. In recent years, our group has correlated NG2 expression poor prognosis...